Dr Kelly Walton

Dr Kelly Walton co-runs the Growth Factor Therapeutics Laboratoryin the Department of Physiology at Monash University.  Her research focus is the large family of Transforming Growth Factor –β (TGF-β) proteins, and their roles in the pathogenesis of reproductive and musculoskeletal disorders. Dr Walton is internationally recognised for her ability to manipulate TGF-β proteins for functional characterisation and for the development of novel TGF-β biologics. Much of her research focuses on a subclass of the TGF-β family, the inhibins and activins, which together coordinate the hypothalamic-pituitary-gonadal axis. Her initial studies defined how inhibins and activins are assembled, enabling the subsequent development of specific anti-activin therapeutics and inhibin mimetics. Significantly, Dr Walton’s team has proven that localised anti-activin therapy can promote substantial muscle growth. Her current program seeks to understand the physiological consequences of inhibin loss at menopause, and the benefits of inhibin therapy on musculoskeletal health. 

Our Sponsors